ABOUT THIS EVENT

Sio Gene Therapies, Inc. (Nasdaq: SIOX), a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease, rings the Nasdaq Closing Bell remotely from across the country.

Pavan Cheruvu, MD, CEO, rings the Closing Bell alongside the Company’s team in a virtual bell ringing ceremony.